Distribution AgreementsAn exclusive distribution agreement for vamorolone has been established in Russia, allowing access to AGAMREE for Duchenne muscular dystrophy patients across the country.
Financial PerformanceSanthera expects FY2025 top-line revenue to exceed the previously stipulated guidance range, suggesting stronger financial performance.
Sales GrowthVamorolone direct sales growth is accelerating in Germany, with increasing use beyond the initial pediatric cohort and rising combination therapy with DUVYZAT™.